Clinical Trials Logo

Lip Augmentation clinical trials

View clinical trials related to Lip Augmentation.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05730543 Completed - Lip Augmentation Clinical Trials

Ethnic Lip Augmentation With Hyaluronic Acid Filler

Start date: November 1, 2022
Phase: Phase 3
Study type: Interventional

Lip augmentation using hyaluronic acid filler in females with Fitzpatrick skin type V-VI

NCT ID: NCT04839692 Completed - Lip Augmentation Clinical Trials

Assessment and Augmentation of Lip Appearance in Specific Study Populations

Start date: May 7, 2021
Phase: Phase 4
Study type: Interventional

This study aims to learn more about the effects of aging and lip filler treatment on lips and the surrounding skin by comparing, among two different age groups of people, changes in the blood vessels and nerves, volume, color and texture change before and after lip filler treatment and pain tolerance from lip filler treatment.

NCT ID: NCT04540913 Completed - Lip Augmentation Clinical Trials

RHA® 3 Versus Restylane-L® for Lip Augmentation

Start date: October 22, 2020
Phase:
Study type: Interventional

This is a multicenter, double-blinded, randomized, prospective, controlled clinical study to identify whether RHA® 3 is non-inferior to Restylane-L® for lip augmentation at Week 12 after the last treatment (initial or touch-up). At screening, the treating investigator (TI) will evaluate the subject's lip fullness using the validated Teoxane Lip Fullness Scale (5-grade) for eligibility of the subject for the study. At screening, the blinded live evaluator (BLE) will evaluate the subject's lip fullness using the TLFS to confirm eligibility and to establish a pre-treatment score for assessment of effectiveness. Enrolled subjects will be randomly assigned in a 3:1 ratio to either the RHA® 3 or the Restylane-L® treatment group. Subjects will be blinded to the study treatment. The TI will administer the fillers, and if necessary, subjects will receive a touch-up treatment 4 weeks after the initial treatment to optimize the results. If the touch-up treatment is administered, the subject will be asked to come to the site for an additional visit 4 weeks after the touch-up injection. The study duration was extended from 36 to 52 weeks once all subjects had already been enrolled. Nearly 60% of the subjects consented to extend the study to 52 weeks before being eligible for repeat treatment. All data are presented up to 52 weeks (as well as 4 more weeks follow-up after retreatment at 36 or 52 weeks). Subjects will be followed for 36 to 52 weeks after their last treatment (initial treatment or touch-up), at which point, they will be offered re-treatment with RHA® 3, regardless of their original treatment, provided that the TI deems the treatment to be appropriate and the subject agrees. Reasons for not administering the re-treatment will be documented. The subject will then be followed for an additional 4 weeks before exiting the study. If the subject or the TI declines re-treatment, this visit (36 or 52 weeks after the last treatment) will be considered the study Exit visit. For subjects with re-treatment, the Exit visit will be 4 weeks after the re-treatment. The TI will conduct safety and effectiveness evaluations at each study visit (up to 36 weeks or 52 (if applicable) weeks after the last treatment, and 4 weeks after re treatment) or until all treatment-related ongoing adverse events (AEs) have resolved or resolved with sequelae as per TI judgment or if follow-up is no longer possible.

NCT ID: NCT04029519 Completed - Lip Augmentation Clinical Trials

A Multicenter, Open-Label Retreatment Study of the Safety and Effectiveness of PN40082 for Lip Augmentation

Start date: December 21, 2018
Phase: Phase 3
Study type: Interventional

To evaluate the safety and efficacy of retreatment with PN40082 for lip augmentation.

NCT ID: NCT03967444 Completed - Lip Augmentation Clinical Trials

Study to Evaluate Satisfaction After Treatment With Kysse

Start date: May 29, 2019
Phase: N/A
Study type: Interventional

Open-label, phase IV, post-marketing study to evaluate aesthetic improvement and satisfaction after treatment with Kysse.

NCT ID: NCT03796728 Completed - Lip Augmentation Clinical Trials

A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT™ With Lidocaine for Lip Augmentation

LIPS
Start date: December 19, 2018
Phase: Phase 4
Study type: Interventional

This is an open-label, multi-center, study where eligible participants will undergo treatment with Juvéderm® VOLIFT™ with Lidocaine injected into the lips for lip augmentation.

NCT ID: NCT03320824 Completed - Lip Augmentation Clinical Trials

New Dermal Filler for Lip Augmentation

Start date: November 13, 2017
Phase: N/A
Study type: Interventional

To demonstrate non-inferiority of Kysse versus a control in lip fullness augmentation

NCT ID: NCT01629134 Completed - Lip Augmentation Clinical Trials

Postmarket Study of JUVÉDERM VOLBELLA™ With Lidocaine in the Lips

Start date: June 2012
Phase: N/A
Study type: Observational

A prospective, multicenter postmarket study of the use of JUVÉDERM VOLBELLA™ with Lidocaine in the lips.

NCT ID: NCT01197495 Completed - Lip Augmentation Clinical Trials

Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augmentation

Start date: August 1, 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate the safety and effectiveness of Juvederm(R) Ultra XC Injectable Gel for lip augmentation

NCT ID: NCT00935272 Completed - Lip Augmentation Clinical Trials

Safety/Efficacy Study of Restylane® in Lip Augmentation

Start date: July 2009
Phase: N/A
Study type: Interventional

To determine the safety and effectiveness of Restylane® when used for lip augmentation.